Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 23andMe, Inc.
Independent Directors of 23andMe Resign from Board
Today 16:26 EDT
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
PTPI
23andMe to Report Q4 and Full Year FY2024 Financial Results
May 09, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe announces CEO’s intention to pursue a potential take-private
April 18, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
March 20, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
March 19, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches New Genetic Reports on Common Forms of Cancer
March 06, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports Third Quarter Fiscal 2024 Financial Results
February 07, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
GSK
ME
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
January 31, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
January 30, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright